Version 1
: Received: 1 November 2024 / Approved: 1 November 2024 / Online: 4 November 2024 (03:49:38 CET)
How to cite:
Park, J.; Kim, J. CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate Cancer. Preprints2024, 2024110055. https://doi.org/10.20944/preprints202411.0055.v1
Park, J.; Kim, J. CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate Cancer. Preprints 2024, 2024110055. https://doi.org/10.20944/preprints202411.0055.v1
Park, J.; Kim, J. CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate Cancer. Preprints2024, 2024110055. https://doi.org/10.20944/preprints202411.0055.v1
APA Style
Park, J., & Kim, J. (2024). CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate Cancer. Preprints. https://doi.org/10.20944/preprints202411.0055.v1
Chicago/Turabian Style
Park, J. and Jaehong Kim. 2024 "CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate Cancer" Preprints. https://doi.org/10.20944/preprints202411.0055.v1
Abstract
Prostate cancer (PCa) is the most prevalent malignancy and the second leading cause of can-cer-related death in men. Although current therapies can effectively manage the primary tumor, most patients with late-stage disease manifest with metastasis in different organs. From surgery to treatment intensification (TI), several combinations of therapies are administered to improve prognosis of patients with metastatic PCa. Due to the high frequency of mutation during the metastatic phase, the Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 genetic engineering tool can accelerate the effects of TI by enhancing targeted gene therapy or immunotherapy. This review describes the genetic backgrounds of metastatic PCa and how CRISPR/Cas9 technology can contribute to the field of PCa treatment development. It also dis-cusses current limitations of conventional PCa therapy and the potential of CRISPR-based-PCa therapy
Keywords
metastatic prostate cancer (mPCa); gene therapy; synthetic lethality, CRISPR-Cas9; DNA damage repair (DDR)
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
